Lexicon Pharmaceuticals (NASDAQ:LXRX) and OSR (NASDAQ:OSRH) Head-To-Head Analysis

Lexicon Pharmaceuticals (NASDAQ:LXRX) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Profitability

This table compares Lexicon Pharmaceuticals and OSR’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
OSR	-593.15%	-8.36%	-6.24%

Volatility and Risk

Lexicon Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Comparatively, OSR has a beta of 0.49, indicating that its share price is 51% less volatile than the S&P 500.

Earnings & Valuation

This table compares Lexicon Pharmaceuticals and OSR”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80 million	18.18	-$50.34 million	($0.15)	-13.57
OSR	$1.81 million	3.59	-$27.06 million	($0.37)	-0.50

OSR has lower revenue, but higher earnings than Lexicon Pharmaceuticals. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than OSR, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 55.3% of OSR shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Lexicon Pharmaceuticals and OSR, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1	1	2	0	2.25
OSR	1	0	0	0	1.00

Lexicon Pharmaceuticals presently has a consensus price target of $4.55, indicating a potential upside of 123.59%. Given Lexicon Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexicon Pharmaceuticals is more favorable than OSR.

Summary

Lexicon Pharmaceuticals beats OSR on 9 of the 14 factors compared between the two stocks.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

About OSR

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D “platform technologies” versus “assets only” companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.